Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
Get Alerts VIR Hot Sheet
Join SI Premium – FREE
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday, April 11, at 11:00 a.m. ET.
The conference will be held virtually. A live webcast of the panel discussion can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

Contacts: Investors Heather Rowe Armstrong VP, Investor Relations [email protected] +1-415-915-4228 Media Carly Scaduto Senior Director, Media Relations [email protected] +1314-368-5189Source: Vir Biotechnology, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QuoMarkets Introduces Weekend XAUUSD Trading as Demand for Continuous Market Access Grows
- Saxena White P.A. Files Securities Fraud Class Action Against DICK’S Sporting Goods, Inc. and Certain of Its Executive Officers and Directors
- Cologne Regional Court Upholds Injunction Against AEKE for Infringing Speediance's Registered Gym Monster Design
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share